| Document |
Document Title |
|
WO/2024/094237A1 |
Novel derivatives of human insulin are described that have binding affinities for the IGF-1 receptor surprisingly comparable to human IGF-1, while having higher affinities for both isoforms of the insulin receptor than human insulin. The...
|
|
WO/2024/097899A1 |
Polynucleotides, expression constructs, compositions, kits and method relating to genetic disorders are disclosed. Some embodiments provided herein encompass variants of a protein that relate to a genetic disorder. Also contemplated are ...
|
|
WO/2024/036193A3 |
Provided are polypeptide comprising a rabies G protein ectodomain. The rabies G protein ectodomain may have a deletion of the fusion loop domain. Further provided are nanoparticle vaccines for rabies virus. Further provided are pharmaceu...
|
|
WO/2024/073097A3 |
Methods and compositions for treatment of geographic atrophy are described. A method of treating a subject suffering from or at risk of geographic atrophy (GA), e.g., GA secondary to age related macular degeneration (AMD), comprising int...
|
|
WO/2024/097696A1 |
Mixed release profiled polymer microsphere formulations comprising octreotide are provided. In one aspect, the microsphere formulations are characterized in that octreotide is released in vivo in humans over a period of about 60 days. Me...
|
|
WO/2024/096133A1 |
The present invention provides a cell-to-cell human T-lymphotropic virus type 1 (HTLV-1) infection inhibitor that contains a substance that inhibits interaction between N-acetyllactosamine (LacNAc) and galectin-3 (Gal-3).
|
|
WO/2024/050056A3 |
Provided are modified arginine deiminase (ADI) proteins, including ADI proteins that comprise one or more substitutions which increase expression in bacteria as insoluble and refoldable inclusion bodies. Also provided are methods of prod...
|
|
WO/2024/097926A1 |
The present invention relates to pharmaceutical dosage forms suitable for gastrointestinal delivery, as well as to methods for the treatment of conditions suitable for treatment by gastrointestinal delivery.
|
|
WO/2024/098078A2 |
The present disclosure is directed to the use of a composition comprised of: (1) a first active blend of at least: (a) Jojoba oil/Macadamia seed oil esters; (b) squalene; (c) phytosteryl macadamiate; and (d) phytosterols; (2) a second ac...
|
|
WO/2024/073420A3 |
Methods and devices for the administration of compositions comprising glutathione trisulfide (GSSSG), pantethine trisulfide (PTN-SSS), or lipoic acid trisulfide (LA-SSS) to treat peripheral neuropathy, e.g., chemotherapy-induced peripher...
|
|
WO/2024/097796A1 |
The present application provides methods of treating a complement-mediated disease in a human individual, comprising administering to the individual an effective amount of a fusion protein comprising i) an antibody moiety that specifical...
|
|
WO/2024/095906A1 |
The purpose of the present invention is to provide a composition or the like for preventing or inhibiting inflammation of neural cells. The present invention relates to a composition for preventing or inhibiting inflammation of neural ce...
|
|
WO/2024/044751A3 |
Provided according to some embodiments is a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions formulated for oral or parenteral administration comprising the same and methods of use for t...
|
|
WO/2024/097767A1 |
The present disclosure provides methods for treating a cancer such as an advanced solid tumor in a subject in need thereof by administering to the subject in need thereof an effective first dose of an IL- 12 albumin binding domain (ABD) ...
|
|
WO/2024/097642A1 |
The present disclosure relates to methods of increasing the efficacy of adoptive cell therapy (ACT) and methods of treating cancer, wherein the methods include administering to a subject with cancer in need thereof a combination therapy ...
|
|
WO/2024/094896A1 |
The present disclosure relates to an anti-fungal composition comprising caspofungin, or a pharmaceutically acceptable salt thereof and at least one bulking agent, which does not comprise a buffering agent; and to a sealed container compr...
|
|
WO/2024/093915A1 |
Provided are a protein comprising an amino acid sequence capable of binding to a substrate GPRP peptide fragment, a fibrinogen like protein 1 (FGL1) comprising the amino acid sequence, and a fibrinogen domain (FD) thereof, and an individ...
|
|
WO/2024/098024A1 |
Methods of expanding peripheral blood lymphocytes (PBLs) from blood of patients with hematological malignancies, including lymphomas and leukemias, genetic modifications of expanded PBLs to incorporate chimeric antigen receptors, genetic...
|
|
WO/2024/096067A1 |
Provided is a cyclic peptide derivative composition for treating or preventing neuropathic pain and/or inflammatory pain. The present disclosure pertains to a composition containing: a compound for treating or preventing neuropathic pa...
|
|
WO/2024/095178A1 |
A method of treating patients suffering from acute liver failure is disclosed. The method comprises administering to a patient in need of treatment an effective amount of a thrombopoietin (TPO) compound alone or combined with another age...
|
|
WO/2023/048639A8 |
Disclosed herein is a compound of formula I: A-[B]n-C I where: A represents a peptide group that targets a viral protease, B, when present, represents a self-immolative linking group, C represents a fluorophore or chemilumiphore group co...
|
|
WO/2024/097708A2 |
A system and method for the production and delivery of biologically active laminin isoform(s) to a target muscle, organ, or system of the body, configured to encourage cell and tissue regeneration and discourage scar formation, facilitat...
|
|
WO/2024/098071A1 |
This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of cardiovascular disease/disorder and/or reducing risk factors thereof by inducing re...
|
|
WO/2024/097731A2 |
The invention relates to methods for treating COVID-19 by targeting the inflammasome/caspase1/pyroptosis axis as a key inflammatory pathway. In particular, the invention relates to treating a patient infected with SARS-CoV-2 with an effe...
|
|
WO/2024/097758A1 |
Provided herein are methods of treating acute leukemia, such as acute myeloid leukemia (AML), in an individual, such as an individual having a mutation within the nucleophosmin 1 (NPM1) gene or a rearrangement within the lysine[K]-methyl...
|
|
WO/2024/073384A3 |
Provided are compositions and uses of the compositions for anti-coagulation purposes. The compositions comprise a peptide component and an anticoagulant. The peptide has the sequence KRWHWWRRHWVVW (SEQ ID NO:1) and optionally comprises a...
|
|
WO/2024/035962A3 |
The invention provides a. genetically modified non-human animal that comprises in its genome foreign γ and δ T cell receptor variable gene coding fragments, as well as its tissues, embryos, and cells. Also provided are constructs and m...
|
|
WO/2024/059753A3 |
This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for inducing weight loss in a human being with fatty liver disease, wherein the human may or may not...
|
|
WO/2024/096742A1 |
The invention is in the field of medical treatment, and relates to a method for treating SARS-CoV-2 infections. In particular, the present invention relates to methods for prophylactic and/or therapeutic treatment of betacoronavirus infe...
|
|
WO/2024/072637A3 |
The invention provides a long-acting parathyroid hormone peptide (PTH) that is retained in a subject's blood serum for periods of time that greatly exceed the natural hormone. The long-acting PTH is conjugated to at the carbon 3 position...
|
|
WO/2024/094597A1 |
The invention relates to methods for the preparation of method of preparation of Tau aggregates, including fibrils, fibrillar species, soluble and insoluble oligomeric species, new Tau aggregates and uses thereof. The invention further r...
|
|
WO/2024/094224A2 |
Provided in the present invention are a PBase protein, a fusion protein, a nucleic acid, a gene integration system, a gene delivery system and the use. The PBase protein retains the abilities of binding to the ITR sequences of a Piggybac...
|
|
WO/2024/097941A1 |
A method of treating malignancy in a subject in need thereof is provided. The method includes administering a therapeutically effective amount of a compound that increases the level of one or more of piR_017723, piR_23656, or piR_016745,...
|
|
WO/2024/094216A1 |
A method for regulating and optimizing a ubiquitin proteasome system and/or an autophagy lysosome system in order to promote the degradation of intracellular and extracellular pathological proteins; a drug for promoting the degradation o...
|
|
WO/2024/050549A3 |
Provided herein are engineered hCMV gB polypeptides. In some aspects, the engineered gB polypeptides exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered gB polypeptides as di...
|
|
WO/2024/044745A3 |
The present disclosure provides pharmaceutical compositions that comprise a microparticle or nanoparticle suspension of a collagen IV-derived peptide or pharmaceutically-acceptable salt thereof, as well as uses of these suspensions for t...
|
|
WO/2024/096261A1 |
The present invention relates to a pharmaceutical composition for treating or preventing autoinflammatory diseases, comprising, as an active ingredient, TLR inhibitor peptide 1 (TIP-1) or MAL/MyD88 inhibitory peptide 2 (MIP-2) or a polyn...
|
|
WO/2024/097448A1 |
Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular, the present technology relates to the use of a recombinant modified vaccinia A...
|
|
WO/2024/096066A1 |
The present disclosure provides a cyclic peptide derivative composition for treating or preventing central nervous system injury/disease. The present disclosure pertains to a composition comprising: a compound for treating or preventin...
|
|
WO/2024/094992A1 |
Disclosed is an aminopeptidase (having a protease associated (PA) domain and a (catalytic) protease domain (PD)) that is self-regulated whereby the C-terminal portion of the aminopeptidase sequence binds in a cleft between the PA domain ...
|
|
WO/2024/097918A1 |
This disclosure provides methods of treating cancers, such as lung cancer, esophageal cancer, renal cancer, and head and neck cancer, with NKG2D fusion proteins, NKG2D fusion proteins for use in methods of treating a subject having cance...
|
|
WO/2024/093473A1 |
The present invention relates to the field of mammalian reproduction. Disclosed is use of a GnRH antagonist in the regulation and control of estrus of a mammal. The GnRH antagonist can inhibit oestrus for a longer time with less frequent...
|
|
WO/2024/031046A3 |
Fusion proteins are provided, which are composed of elements such as one or more proteins/polypeptides capable of translocating into an endoplasmic reticulum (ER) and an interleukin 18 (IL-18) or a fragment or variant of IL-18. The prote...
|
|
WO/2024/093056A1 |
The present invention relates to a T cell receptor (TCR) specifically binding to a KRAS_G12V mutant antigen, a fusion protein or conjugate comprising the TCR, a nucleic acid encoding the TCR and an engineered cell comprising same, and a ...
|
|
WO/2024/097852A1 |
This document relates to methods and materials for using engineered mesenchymal stromal cells (MSCs) to treat a mammal (e.g., a human) in need of immunosuppression (e.g., a human having or at risk of developing one or more autoimmune dis...
|
|
WO/2023/034614A9 |
Systems and methods for nerve repair can include a polymer configured to form an elongated conduit to receive an in vivo nerve therein and provide a mechanical stabilization to the in vivo nerve. The polymer can be configured to degrade ...
|
|
WO/2024/094685A1 |
The present invention relates to CCR2 inhibitors that are variant CCL2 polypeptides comprising a variant N-terminal portion and a conserved C-terminal portion, and peptides and uses thereof.
|
|
WO/2024/073399A3 |
Provided herein are nanostructures comprising peptides specific for the extracellular domains of HER1 and/or HER3. Also provided herein are methods for use of the nanostructures to aggregate cells and deliver therapeutic agents to the ce...
|
|
WO/2024/092717A1 |
Provided is a protein derived from a fibronectin type III domain, and the use thereof. The protein comprises the 10th human fibronectin type III domain, and comprises a first mutation where one amino acid site is substituted with one cys...
|
|
WO/2024/097772A1 |
The present application provides compositions for treatment of Friedreich's Ataxia (FA). These include, but are not limited to, nucleic acid constructs and recombinant AAV7 vectors comprising a human frataxin 5' untranslated region (5'UT...
|
